TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC

NCT04992143 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

BCLC Stage C Hepatocellular Carcinoma

Interventions

PROCEDURE: TACE
DRUG: Tilelizumab
DRUG: Sorafenib

Sponsor

First Affiliated Hospital of Zhejiang University